LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Medtronic PLC

Slēgts

SektorsVeselības aprūpe

94.03 1.24

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

92.93

Max

94.27

Galvenie mērījumi

By Trading Economics

Ienākumi

-17M

1B

Pārdošana

-349M

8.6B

P/E

Sektora vidējais

25.638

35.733

EPS

1.26

Dividenžu ienesīgums

3.06

Peļņas marža

12.124

Darbinieki

95,000

EBITDA

-50M

2.2B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+7.42% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.06%

3.13%

Nākamie ieņēmumi

2025. g. 18. nov.

Nākamais dividenžu datums

2025. g. 17. okt.

Nākamais Ex dividenžu datums

2025. g. 26. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

133M

119B

Iepriekšējā atvēršanas cena

92.79

Iepriekšējā slēgšanas cena

94.03

Ziņu noskaņojums

By Acuity

26%

74%

82 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Medtronic PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. aug. 11:39 UTC

Peļņas

Medtronic Posts Higher 1Q Revenue, Boosts Outlook as Tariffs Ease

2025. g. 21. maijs 11:38 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

2025. g. 19. aug. 20:33 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More -- Barrons.com

2025. g. 19. aug. 17:41 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025. g. 19. aug. 13:35 UTC

Karstas akcijas

Stocks to Watch Tuesday: Intel, Medtronic, Home Depot -- WSJ

2025. g. 19. aug. 12:48 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025. g. 19. aug. 11:27 UTC

Peļņas

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025. g. 19. aug. 10:51 UTC

Peļņas

Medtronic Sees FY26 Reported Revenue Growth 6.5%-6.8% >MDT

2025. g. 19. aug. 10:50 UTC

Peļņas

Medtronic Had Seen FY26 Adjusted EPS $5.50-$5.60 >MDT

2025. g. 19. aug. 10:50 UTC

Peļņas

Medtronic Raises FY26 View To Adj EPS $5.60-Adj EPS $5.66 >MDT

2025. g. 19. aug. 10:50 UTC

Peļņas

Medtronic Cuts FY26 Potential Tariff Impact View to About $185M From $200M-$350M >MDT

2025. g. 19. aug. 10:49 UTC

Peļņas

Medtronic Raises FY26 Adjusted EPS Growth View to About 4.5% From About 4%, Excluding Potential Tariff Impact >MDT

2025. g. 19. aug. 10:48 UTC

Peļņas

Medtronic Still Sees FY26 Organic Revenue Up About 5% >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Medical Surgical Portfolio Rev $2.08B >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Cardiovascular Portfolio Rev $3.29B >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Neuroscience Portfolio Rev $2.42B >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Organic Revenue Up 4.8% >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q EPS 81c >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Net $1.04B >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Diabetes Rev $721M >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Sales $8.58B >MDT

2025. g. 19. aug. 10:45 UTC

Peļņas

Medtronic 1Q Adj EPS $1.26 >MDT

2025. g. 19. aug. 09:12 UTC

Karstas akcijas

Stocks to Watch Tuesday: Intel, Palo Alto, Tegna, Home Depot -- WSJ

2025. g. 12. jūn. 13:01 UTC

Iegādes, apvienošanās, pārņemšana

Medtronic Targeting Completion of Planned Separation Within 18 Mos of Initial Announcement >MDT

2025. g. 21. maijs 17:23 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

2025. g. 21. maijs 11:39 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

2025. g. 21. maijs 10:52 UTC

Peļņas

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

2025. g. 21. maijs 10:51 UTC

Peļņas

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

2025. g. 21. maijs 10:50 UTC

Peļņas

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

2025. g. 21. maijs 10:49 UTC

Peļņas

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

Salīdzinājums

Cenas izmaiņa

Medtronic PLC Prognoze

Cenas mērķis

By TipRanks

7.42% augšup

Prognoze 12 mēnešiem

Vidējais 99.89 USD  7.42%

Augstākais 115 USD

Zemākais 78 USD

Pamatojoties uz 26 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Medtronic PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

26 ratings

13

Pirkt

12

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

83.26 / 84.875Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

82 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat